Markets
BSE See NSE See 49,206.47
256.71 (0.52%)

Natco Pharma shines on getting nod from CDSCO for emergency use of Baricitinib tablets

Apurva Joshi / Article rating: 5.0

Natco Pharma Limited has informed the bourses that it has received emergency use approval for Baricitinib tablets in strengths of 1 mg, 2 mg, and 4 mg from Central Drugs Standard Control Organisation (CDSCO), India. Baricitinib, combined with Remdesivir, is used for the treatment of COVID-19 positive patients.

1345678910Last

Get A Call From Industry Experts

Send Otp

   I authorize DSIJ Pvt Ltd to contact me. This will override registry on the NDNC.

DSIJ MINDSHARE

1345Last

Knowledge

1345Last